Company intelligence / Profile preview

Viridian Strategies

Waltham, Massachusetts, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Viridian Therapeutics develops best-in-class monoclonal antibodies for serious and rare autoimmune diseases. Its lead program veligrotug has demonstrated positive Phase 3 results in thyroid eye disease with plans to submit a BLA by late 2025. Additional pipeline assets include subcutaneous TED therapies and novel FcRn inhibitors for broader autoimmune applications. The company holds strong cash reserves ($700M+), supporting operations through anticipated commercial launch.

Therapeutic areas: EndocrinologyImmunology
Modalities: Monoclonal antibody (veligrotug, VRDN-003)Antibody (general platform for pipeline candidates)FcRn inhibitor (VRDN-006, VRDN-008)
Industry: Biotech

Partnerships

No major pharma partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Viridian Strategies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viridian Strategies.

Explore the full profile